Hyperkalemia in chronic heart failure with renal dysfunction or diabetes mellitus: Results from the TREAT HF study

MURAT S., KAYA H., ÇAVUŞOĞLU Y., YILMAZ M. B.

TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, vol.49, no.3, pp.198-205, 2021 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 49 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.5543/tkda.2021.58675
  • Journal Name: TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Central & Eastern European Academic Source (CEEAS), EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.198-205
  • Keywords: Hyperkalemia, heart failure, diabetes mellitus, chronic kidney disease, CONVERTING-ENZYME-INHIBITORS, VENTRICULAR SYSTOLIC FUNCTION, SERUM POTASSIUM, PREDICTORS, RISK, ASSOCIATION, CANDESARTAN, ALISKIREN, OUTCOMES
  • Çanakkale Onsekiz Mart University Affiliated: Yes

Abstract

Objective: Chronic kidney disease (CKD) and diabetes mellitus (DM) are common comorbidities in heart failure (HF). Patients with HF are at a high risk of hyperkalemia, and are therefore undertreated with respect to disease-modifying therapies. The Turkish Research Team-Heart Failure (TREAT HF) data were analyzed for the evaluation of hyperkalemia in real-life clinical practice in HF patients with CKD or DM.